ArticleAdvances in radiation oncology2026
Preoperative Fractionated Stereotactic Radiosurgery for Brain Metastases: A Prospective Pilot Study at a Single Institution.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment on: "Neoadjuvant gamma knife surgery for metastatic brain tumor: clinical use and impact on leptomeningeal seeding".Journal of neuro-oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Brain metastases are a common occurrence in patients with advanced malignancy. Treatment ranges from surgical resection, stereotactic radiosurgery (SRS), whole-brain radiation therapy (WBRT), or some combination thereof. Traditionally, SRS has followed surgical resection to help reduce the risk of local recurrence. In recent years, interest has arisen in treating these patients in the preoperative setting to help reduce the risk of leptomeningeal disease (LMD) and radiation necrosis while preserving rates of local control. This prospective pilot study, originally planned as a phase 2 protocol, investigated the use of 3-fraction preoperative SRS on the Gamma Knife (GK) Icon with the goal of examining those outcomes. Methods and Materials: Patients who had symptomatic and a limited number of brain metastases amenable to surgical resection were prospectively enrolled in this study. Patients were treated with fractionated SRS on the GK Icon to 24 to 27 Gy in 3 fractions followed by surgical resection within 2 weeks. Postoperative MRIs were obtained to assess the extent of resection. Patients were then followed up with standard-of-care MRIs every 3 months for the first 2 years. Rates of local control, distant brain failure, LMD, and delivery of WBRT were recorded on follow-up. Results: Twenty patients were prospectively enrolled in the trial, and an additional 11 were treated off study using 1 to 3 fractions between April 2021 and June 2024. The median age was 64 (31-81), and 55% were females. Primary malignancies were mainly non-small cell lung cancer, melanoma, and esophageal cancer. The median prescription dose was 27 Gy (15-27 Gy) in 3 (1-3) fractions. Surgery was performed at a median of 1 day post-SRS (0-11). All available postoperative MRIs showed gross total resection. Median follow-up was 9 months. One patient experienced a local failure, yielding a 1-year local control rate of 95%. The rate of distant brain failure at 6 and 12 months was 38% at each time point. Three patients (9.6%) developed LMD in follow-up. Six patients ultimately received WBRT, yielding a 1-year WBRT-free survival of 78%. Overall survival at 1 year was 52%. There were no predictors of overall survival, local failure, or distant brain failure on Cox regression. Two patients experienced short-term toxicity, including grade 2 intracranial swelling and one grade 5 hemorrhagic stroke related to a hypertensive crisis. There was no recorded radionecrosis in follow-up. Conclusions: Fractionated preoperative SRS appears to be safe and effective with high rates of local control and low rates of LMD and radionecrosis. Results of ongoing phase 3 studies directly comparing preoperative to postoperative SRS will help further define the appropriate sequencing of therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.